A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS RELATIVE BIOAVAILABILITY OF PF-08653944 WHEN ADMINISTERED ACROSS DIFFERENT INJECTION SITES IN ADULTS WITH OVERWEIGHT OR OBESITY
Latest Information Update: 03 Mar 2026
At a glance
- Drugs MET 097i (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 27 Feb 2026 Status changed from not yet recruiting to recruiting.
- 16 Feb 2026 New trial record